Medable, Inc., a Palo Alto, Calif.-based provider of a digital platform to decentralize clinical trials, raised $78m in funding.
The round was led by Sapphire Ventures, with participation from new investor Obvious Ventures and follow-on investment from existing investors GSR Ventures, PPD, Inc. (Nasdaq:PPD) and Streamlined Ventures.
The company, which has raised more than $217m to date, intends to use the funds to continue enabling broad adoption of digital trials and patient-centric strategies at global scale. Key focus areas include internal initiatives related to ubiquitous research access, patient data fluidity, and intelligent monitoring of patients and clinical trial data.
Led by Dr. Michelle Longmire, CEO and co-founder, Medable provides a digital platform that streamlines design, recruitment, retention and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. The solution connects patients, sites and clinical trial teams to improve patient access, experience, and outcomes.
The platform has been used for clinical trials across a variety of therapeutic areas in more than 60 countries, enabling participation in over 40 languages.